TPMT activity is essential in cancer treatment because it influences the efficacy and toxicity of thiopurine drugs. Patients with low or absent TPMT activity are at a higher risk of severe myelosuppression when treated with standard doses of thiopurines. Therefore, understanding a patient's TPMT status can guide dosage adjustments to minimize toxicity and optimize therapeutic outcomes.
